GastroenterologyNews.net

Gastroenterology Xagena

Xagena Mappa
Medical Meeting
Pneumobase.it
Dermabase.it

Effectiveness of Rifaximin in prevention of diarrhoea in individuals travelling to south and southeast Asia


Travellers' diarrhoea causes substantial acute and long-term morbidity. Chemoprophylaxis with fluoroquinolones or Rifaximin ( Normix, Xifaxan ) is effective in prevention of diarrhoea in individuals travelling to Latin America and Africa. Little evidence is available to support the protective effect of antimicrobial drugs in south and southeast Asia, where enteroinvasive and antibiotic-resistant bacteria cause a substantial proportion of diarrhoeal episodes.
A study has assessed the effectiveness of Rifaximin in prevention of diarrhoea in individuals travelling to south and southeast Asia.

Researchers did this double-blind, placebo-controlled, single-centre, parallel-group, clinical trial in Tübingen, Germany, during the period 2009-2012.

Individuals aged 18-64 years who were planning a 6-28 day journey to south and southeast Asia were randomly assigned ( 1:1 ) to receive placebo or Rifaximin 200 mg tablets twice daily.
All members of the study team, including investigators, those assessing outcomes, and data analysts, were masked to treatment allocation.

The primary endpoint was time to the first episode of classic travellers' diarrhoea, defined as three or more loose stools in 24 h, accompanied by one or more enteric symptoms.
Analyses were by intention to treat and per protocol.

Investigators have randomly assigned 258 participants to Rifaximin ( n=129 ) or placebo ( n=129 ), of whom 239 ( 93% ) returned a completed diary and were included in the primary effectiveness analysis. 48 ( 41% ) of 117 participants in the placebo group and 30 ( 25% ) of 122 in the Rifaximin group reported classic episodes of travellers' diarrhoea.

From departure to 7 days after return, Rifaximin provided 48% protection by lowering the incidence of travellers' diarrhoea from 1.99 per 100 person-days in the placebo group to 1.04 in the intervention group ( incidence rate ratio 0.52; p=0.005 ).

The number needed to treat ( NNT ) was 5.70 to prevent one case of classic travellers' diarrhoea during the first 3 weeks of follow-up.

The per-protocol analysis essentially corroborated the findings from the intention-to-treat analysis.

One serious adverse event in a participant in the Rifaximin group who had grade 3 right lower quadrant abdominal pain 72 h after the last intake of study drug, was recorded. The complaints were considered unlikely to be related to use of the drug.

In conclusion, Rifaximin is moderately effective in prevention of diarrhoea in individuals travelling to south and southeast Asia. ( Xagena )

Zanger P et al, The Lancet Infectious Diseases 2013; 13: 946-954

XagenaMedicine_2013



Indietro